Cargando…

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics

Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein(a) [Lp(a)]-targeting therapy has yet been shown to reduce cardiovascular disease risk. Many ep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swerdlow, Daniel I, Rider, David A, Yavari, Arash, Wikström Lindholm, Marie, Campion, Giles V, Nissen, Steven E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953457/ https://www.ncbi.nlm.nih.gov/pubmed/33769464 http://dx.doi.org/10.1093/cvr/cvab100

Ejemplares similares

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease
por: Rider, David, et al.
Publicado: (2022)

Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
por: Millán, Jesús, et al.
Publicado: (2009)

Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations
por: Pearson, Keon, et al.
Publicado: (2020)

Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
por: Maloberti, Alessandro, et al.
Publicado: (2022)

Cytokine response to lipoprotein lipid loading in human monocyte-derived macrophages
por: Persson, Jenny, et al.
Publicado: (2006)

Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention
por: Koutsogianni, Amalia Despoina, et al.
Publicado: (2022)

Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities
por: Seropian, Ignacio M., et al.
Publicado: (2018)

Lipoprotein(a) in Cardiovascular Diseases
por: Malaguarnera, Michele, et al.
Publicado: (2013)

Native High Density Lipoproteins (HDL) Interfere with Platelet Activation Induced by Oxidized Low Density Lipoproteins (OxLDL)
por: Badrnya, Sigrun, et al.
Publicado: (2013)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Swi/Snf Chromatin Remodeling Regulates Transcriptional Interference and Gene Repression
por: Morse, Kaitlin, et al.
Publicado: (2023)

The role of autophagy in cardiovascular disease: Cross-interference of signaling pathways and underlying therapeutic targets
por: Jiang, Bing, et al.
Publicado: (2023)

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Tamoxifen, serum lipoproteins and cardiovascular risk.
por: Bruning, P. F., et al.
Publicado: (1988)

Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies
por: Bhatia, Harpreet S., et al.
Publicado: (2022)

The therapeutic potential of RNA interference
por: Uprichard, Susan L.
Publicado: (2005)

RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant
por: Wu, Hui-Lin, et al.
Publicado: (2005)

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
por: Rizvi, Ali A., et al.
Publicado: (2021)

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
por: Ginsberg, Henry N, et al.
Publicado: (2021)

Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data
por: Mathews, Simon C., et al.
Publicado: (2012)

Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges
por: Tintut, Yin, et al.
Publicado: (2018)

Lipoprotein (a), an independent cardiovascular risk marker
por: Saeedi, Ramesh, et al.
Publicado: (2016)

Recent Updates of Lipoprotein(a) and Cardiovascular Disease
por: Liu, Taili, et al.
Publicado: (2021)

High-Density Lipoproteins in Non-Cardiovascular Diseases
por: Zanotti, Ilaria
Publicado: (2022)

The Outer Surface Lipoprotein VolA Mediates Utilization of Exogenous Lipids by Vibrio cholerae
por: Pride, Aaron C., et al.
Publicado: (2013)

Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets
por: Silverio, Angelo, et al.
Publicado: (2023)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

Ethical Perspectives on RNA Interference Therapeutics
por: Ebbesen, Mette, et al.
Publicado: (2008)

RNA Interference Mechanisms and Therapeutic Applications
por: Lamers, Anne E., et al.
Publicado: (2006)

RNA Interference: RNAid for Future Therapeutics?
por: Diallo, Mustapha, et al.
Publicado: (2005)

Epigenetic associations in relation to cardiovascular prevention and therapeutics
por: Voelter-Mahlknecht, Susanne
Publicado: (2016)

High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
por: Androulakis, Emmanuel, et al.
Publicado: (2017)

Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related Disorders
por: Weingärtner, Adrien, et al.
Publicado: (2020)

Engineering miRNA features into siRNAs: Guide-strand bulges are compatible with gene repression
por: Hauptmann, Judith, et al.
Publicado: (2022)

Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis
por: Dancevic, Carolyn M, et al.
Publicado: (2014)

Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound
por: Huded, Chetan P., et al.
Publicado: (2020)

Statins for primary cardiovascular disease prevention among people with HIV: emergent directions
por: Fitch, Kathleen V., et al.
Publicado: (2022)

Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus
por: Enkhmaa, Byambaa, et al.
Publicado: (2010)

High density lipoproteins-based therapies for cardiovascular disease
por: Gao, Xuan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_gdvkrkuqk41ftrkdbnuf7apm0u